OncoMatch/Clinical Trials/NCT07312630
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
Is NCT07312630 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies LV009 for non-hodgkin lymphoma (nhl).
Treatment: LV009 — Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received:
Meets the NCCN guidelines' criteria for recurrence/refractory disease
Lab requirements
Blood counts
Absolute lymphocyte count ≥ 0.5 × 10⁹/L; platelet count ≥ 50 × 10⁹/L; CD3-positive T cells ≥ 150 cells/μL
Kidney function
Kidney function meets requirements
Liver function
Liver function meets requirements
Cardiac function
Cardiopulmonary function meets requirements; exclusion of severe cardiac conditions including but not limited to: unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA class ≥ III), and severe arrhythmias
Liver and kidney function, as well as cardiopulmonary function, meet requirements. Absolute lymphocyte count ≥ 0.5 × 10⁹/L; platelet count ≥ 50 × 10⁹/L; CD3-positive T cells ≥ 150 cells/μL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify